Schering-Plough over the past
year," said Hassan. "I thank Ruurd for his leadership, guidance and
important contributions bringing our two companies together. Raul and I
look forward to working with him in an advisory capacity."
Schering-Plough is an innovation-driven, science-centered global health
care company. Through its own biopharmaceutical research and collaborations
with partners, Schering-Plough creates therapies that help save and improve
lives around the world. The company applies its research-and-development
platform to human prescription and consumer products as well as to animal
health products. Schering-Plough's vision is to "Earn Trust, Every Day"
with the doctors, patients, customers and other stakeholders served by its
colleagues around the world. The company is based in Kenilworth, N.J., and
its Web site is http://www.schering-plough.com.
Media Contact
Steve Galpin, Jr.
+1 908 298 7415
Sabine Schueller
+31 485 58 7085
Investor Contacts
Janet Barth
Joseph Romanelli
+1 908 298 7436
'/>"/>SOURCE Schering-Plough Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine news :1.
Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture2.
Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck3.
Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 20174.
Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia5.
Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management6.
Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference7.
Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain8.
CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough9.
Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough10.
Schering-Plough CEO to Buy $2 Million in Common Shares11.
Schering-Plough Board Elects Dr. Craig B. Thompson as a Director